Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study
Hirschfield, GM; Shiffman, ML; Gulamhusein, A; Kowdley, K; Vierling, JM; Levy, C; Kremer, AE; Zigmond, E; Andreone, P; Gordon, SC; Bowlus, CL; Lawitz, EJ; Aspinall, RJ; Pratt, DS; Raikhelson, K; Gonzalez-Huezo, MS; Heneghan, MA; Jeong, SH; de Guevara, ALL; Mayo, MJ; Dalekos, GN; Drenth, JPH; Janczewska, E; Leggett, BA; Nevens, F; Vargas, V; Zuckerman, E; Corpechot, C; Fassio, E; Hinrichsen, H; Invernizzi, P; Trivedi, PJ; Forman, L; Jones, DEJ; Ryder, SD; Swain, MG; Steinberg, A; Boudes, PF; Choi, YJ; McWherter, CA
Hirschfield, GM (通讯作者)，Toronto Gen Hosp, Toronto Ctr Liver Dis, 9th Floor Eaton Bldg,North Wing 219-B,200 Elizabe, Toronto, ON M5G 2C4, Canada.
HEPATOLOGY, 2023; 78 (2): 397
